Monte Rosa Therapeutics (GLUE) Competitors $5.68 +0.46 (+8.70%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. ABCL, PAHC, NTLA, WVE, COGT, CVAC, AUPH, CALT, HROW, and ARDXShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Intellia Therapeutics (NTLA), WAVE Life Sciences (WVE), Cogent Biosciences (COGT), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Its Competitors AbCellera Biologics Phibro Animal Health Intellia Therapeutics WAVE Life Sciences Cogent Biosciences CureVac Aurinia Pharmaceuticals Calliditas Therapeutics AB (publ) Harrow Ardelyx Monte Rosa Therapeutics (NASDAQ:GLUE) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Do analysts rate GLUE or ABCL? Monte Rosa Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 169.72%. AbCellera Biologics has a consensus price target of $8.75, suggesting a potential upside of 116.32%. Given Monte Rosa Therapeutics' higher probable upside, research analysts clearly believe Monte Rosa Therapeutics is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is GLUE or ABCL more profitable? Monte Rosa Therapeutics has a net margin of 3.86% compared to AbCellera Biologics' net margin of -737.56%. Monte Rosa Therapeutics' return on equity of 2.65% beat AbCellera Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics3.86% 2.65% 1.65% AbCellera Biologics -737.56%-15.98%-12.38% Does the media prefer GLUE or ABCL? In the previous week, AbCellera Biologics had 11 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 12 mentions for AbCellera Biologics and 1 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.87 beat AbCellera Biologics' score of 0.85 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Monte Rosa Therapeutics Very Positive AbCellera Biologics Positive Which has better earnings and valuation, GLUE or ABCL? Monte Rosa Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M4.62-$72.70M$0.0871.06AbCellera Biologics$23.11M52.22-$162.86M-$0.56-7.22 Do institutionals & insiders believe in GLUE or ABCL? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 28.9% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, GLUE or ABCL? Monte Rosa Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. SummaryMonte Rosa Therapeutics beats AbCellera Biologics on 11 of the 17 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$349.62M$2.92B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E Ratio71.0620.4028.6319.71Price / Sales4.62300.36439.46185.19Price / CashN/A43.1536.0257.93Price / Book1.577.748.195.65Net Income-$72.70M-$55.11M$3.24B$257.81M7 Day Performance7.47%0.68%-0.07%0.37%1 Month Performance17.95%8.14%5.52%8.66%1 Year Performance16.74%-2.64%26.39%14.04% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.1704 of 5 stars$5.69+8.7%$15.33+169.7%+24.8%$349.62M$75.62M71.0690Positive NewsABCLAbCellera Biologics2.2851 of 5 stars$4.25+0.7%$7.50+76.5%+23.1%$1.27B$23.11M-7.59500Analyst ForecastPAHCPhibro Animal Health3.9876 of 5 stars$31.14-0.8%$24.40-21.6%+73.6%$1.26B$1.02B39.921,940NTLAIntellia Therapeutics4.3808 of 5 stars$12.16+0.2%$33.37+174.4%-55.9%$1.26B$57.88M-2.33600WVEWAVE Life Sciences4.4941 of 5 stars$7.95+3.2%$20.50+157.9%+28.7%$1.24B$108.30M-9.46240News CoverageAnalyst ForecastGap UpCOGTCogent Biosciences3.5514 of 5 stars$10.85+4.3%$18.00+65.9%+24.3%$1.24BN/A-5.9080Insider TradeAnalyst RevisionHigh Trading VolumeCVACCureVac4.7222 of 5 stars$5.45-0.9%$6.83+25.4%+50.3%$1.22B$523.70M5.92880Positive NewsAUPHAurinia Pharmaceuticals3.155 of 5 stars$8.93+6.4%$11.50+28.8%+58.6%$1.21B$235.13M31.89300High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180HROWHarrow2.375 of 5 stars$31.37-0.9%$61.40+95.7%+38.3%$1.15B$212.86M-56.02180Analyst RevisionARDXArdelyx4.0603 of 5 stars$4.70+2.2%$10.89+131.7%-24.4%$1.12B$333.61M-21.3690Analyst Revision Related Companies and Tools Related Companies ABCL Alternatives PAHC Alternatives NTLA Alternatives WVE Alternatives COGT Alternatives CVAC Alternatives AUPH Alternatives CALT Alternatives HROW Alternatives ARDX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLUE Stock Alerts